Acura Pharmaceuticals (ACUR) 10-Q 4 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	786,947
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		11,800,986

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 3,324	$ 774
Marketable securities (Note 6)	11,929	11,322
Accounts receivable, net of allowances of $88 and $5	167	76
Accrued investment income	51	66
Inventories, net (Note 7)	74	304
Prepaid expenses and other current assets	488	471
Other current deferred assets	1	218
Total current assets	16,034	13,231
Property, plant and equipment, net (Note 8)	1,042	957
Intangible asset, net of accumulated amortization of $310 and $155 (Note 3)	1,690	1,845
Other assets	175	0
Total assets	18,941	16,033
Current liabilities:
Accounts payable	276	217
Accrued expenses (Note 9)	825	568
Other current liabilities	33	26
Accrued interest	62	70
Sales returns liability	173	0
Deferred revenue	0	353
Current maturities of long-term debt (Note 10)	2,470	1,758
Total current liabilities	3,839	2,992
Long-term debt, net of discount of $220 and $281, and debt issuance costs of $112 and $162 (Note 10)	6,038	7,799
Long-term portion of accrued interest	339	190
Total liabilities	$ 10,216	$ 10,981
Commitments and contingencies (Note 16)
Stockholders' equity:
Common stock: $.01 par value per share; 100,000 shares authorized, 11,801 and 9,770 shares issued and outstanding at 2015 and 2014, respectively	$ 118	$ 98
Additional paid-in capital	375,012	367,288
Accumulated deficit	(366,394)	(362,321)
Accumulated other comprehensive loss	(11)	(13)
Total stockholders' equity	8,725	5,052
Total liabilities and stockholders' equity	$ 18,941	$ 16,033

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accounts receivable, net of allowances	$ 88	$ 5
Finite-lived intangible assets accumulated amortization	310	155
Long-term debt, net of debt discount	220	281
Debt Instrument Issuance Cost	$ 112	$ 162
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	11,801	9,770
Common stock, shares outstanding	11,801	9,770

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
License fee revenue	$ 0	$ 0	$ 5,250	$ 0
Collaboration revenue	95	0	95	0
Royalty revenue	0	0	0	4
Product sales, net	115	145	563	218
Total revenues, net	210	145	5,908	222
Cost and expenses:
Cost of sales (excluding inventory write-down)	132	108	554	188
Inventory write-down (Note 7)	27	0	334	201
Research and development	432	955	1,907	3,674
Selling, marketing, general and administrative	2,024	1,728	6,404	5,903
Total costs and expenses	2,615	2,791	9,199	9,966
Operating loss	(2,405)	(2,646)	(3,291)	(9,744)
Non-Operating income (expense):
Investment income	39	46	110	143
Interest expense (Note 10)	(283)	(304)	(892)	(907)
Other expense	0	0	0	(5)
Total other expense, net	(244)	(258)	(782)	(769)
Loss before provision for income taxes	(2,649)	(2,904)	(4,073)	(10,513)
Provision for income taxes	0	0	0	0
Net loss	(2,649)	(2,904)	(4,073)	(10,513)
Other comprehensive income (loss):
Unrealized gains (losses) on securities	2	(44)	2	6
Total other comprehensive income (loss)	2	(44)	2	6
Comprehensive loss	$ (2,647)	$ (2,948)	$ (4,071)	$ (10,507)
Loss per share of common stock:
Basic	$ (0.23)	$ (0.3)	$ (0.39)	$ (1.08)
Diluted	$ (0.23)	$ (0.3)	$ (0.39)	$ (1.08)
Weighted average shares outstanding:
Basic	11,677	9,784	10,446	9,774
Diluted	11,677	9,784	10,446	9,774

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - 9 months ended Sep. 30, 2015 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2014	$ 5,052	$ 98	$ 367,288	$ (362,321)	$ (13)
Balance (in shares) at Dec. 31, 2014		9,770
Net loss	(4,073)	$ 0	0	(4,073)	0
Other comprehensive income (loss)	2	0	0	0	2
Share-based compensation	461	0	461	0	0
Net distribution of common stock pursuant to restricted stock unit award plan	1	$ 1	0	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		19
Modification to warrants issued with promissory notes	33	$ 0	33	0	0
Issuance of common stock under “at the market” offerings, net of offering costs of $8	217	$ 0	217	0	0
Issuance of common stock under “at the market” offerings, net of offering costs of $8 (in shares)		54
Issuance of common stock under registered direct offering, net of offering costs of $603	7,032	$ 19	7,013	0	0
Issuance of common stock under registered direct offering, net of offering costs of $603 (in shares)		1,958
Balance at Sep. 30, 2015	$ 8,725	$ 118	$ 375,012	$ (366,394)	$ (11)
Balance (in shares) at Sep. 30, 2015		11,801

CONSOLIDATED STATEMENTS OF CHA6

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) $ in Thousands	Sep. 30, 2015USD ($)
Direct Offering [Member]
Deferred Offering Costs	$ 603
Market Offering [Member]
Deferred Offering Costs	$ 8

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows from Operating Activities:
Net loss	$ (4,073)	$ (10,513)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	92	90
Provision to reduce inventory to net realizable value	334	201
Provision for sales returns	253	0
Share-based compensation	461	716
Amortization of debt discount and debt issue costs	144	140
Amortization of bond premium in marketable securities	106	201
Amortization of intangible asset	155	0
Loss on sales of marketable securities	0	5
Loss on disposal of property and equipment	20	1
Changes in assets and liabilities:
Accounts receivable, net	(171)	62
Accrued investment income	15	28
Inventories	(104)	(353)
Prepaid expenses and other current assets	(17)	(183)
Other current deferred assets	217	46
Other assets	(175)	4
Accounts payable	59	(158)
Accrued expenses	257	1,087
Deferred revenue	(353)	(59)
Accrued interest - current and long term	141	0
Other current liabilities	7	0
Net cash used in operating activities	(2,632)	(8,685)
Cash Flows from Investing Activities:
Purchases of marketable securities	(3,523)	(2,203)
Proceeds from sale and maturities of marketable securities	2,811	2,424
Acquisition of product rights	0	(2,000)
Additions to property, plant and equipment	(211)	(105)
Proceeds from disposal of property and equipment	14	0
Net cash used in investing activities	(909)	(1,884)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	8
Proceeds from distribution of restricted stock units	1	1
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options	0	(529)
Proceeds from “at-the-market” offering	225	0
Proceeds from registered direct offering	7,636	0
Offering transaction costs	(611)	0
Principal payments on debt	(1,160)	0
Net cash provided by (used) in financing activities	6,091	(520)
Net increase (decrease) in cash and cash equivalents	2,550	(11,089)
Cash and cash equivalents at beginning of year	774	12,340
Cash and cash equivalents at end of period	3,324	1,251
Cash paid during the period for:
Interest	606	557
Income taxes	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CAS8

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Outstanding	60
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52
Additions To Debt Instrument Unamortized Discount	$ 33
Maximum [Member]
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8
Minimum [Member]
Supplemental Disclosure of Noncash Financing Activities:
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52
Stock options
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		5
Common stock withheld in exercise costs in shares		3
Common stock withheld in exercise costs		$ 32
Withholding of exercise cost in shares		1
Minimum statutory withholding payroll taxes withheld		$ 4
Common Stock issued upon exercise		1
Restricted Stock Units (RSUs) [Member]
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		165
Common stock withheld in exercise costs in shares		1
Common stock withheld in exercise costs		$ 7
Withholding of exercise cost in shares		63
Minimum statutory withholding payroll taxes withheld		$ 525
Common Stock issued upon exercise		102

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2015
Description Of Business Disclosure [Abstract]
DESCRIPTION OF BUSINESS	NOTE 1 - DESCRIPTION OF BUSINESS Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Oxaydo™ Tablets (formerly known as Oxecta®) (oxycodone HCl, CII), is the first approved product utilizing Aversion® in the United States. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the U.S. Food and Drug Administration, or FDA, for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. We have also developed Impede® Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. We launched our first Impede Technology product, Nexafed®, into the United States market in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC (“Bayer”) entered into a License and Development Agreement to provide Bayer with an exclusive worldwide license to our Impede Technology for an undisclosed methamphetamine resistant pseudoephedrine – containing product, and providing for our joint development of such product utilizing our Impede™ Technology for the U.S. market. Our third technology, Limitx, is designed to retard the release of active drug ingredients when an excess number of tablets are accidently or purposefully ingested. In August 2014, we were awarded a $300 thousand grant from the National Institute on Drug Abuse to advance early stage development of our Limitx technology, of which we have received $237 thousand of the grant through September 30, 2015. Amounts presented have been rounded to the nearest thousand, where indicated, except share and per share data. The equity amounts and all share and per share data of the Company have been retroactively adjusted to reflect a one-for-five reverse stock split on August 28, 2015.

ACCOUNTING PRONOUNCEMENTS

ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
ACCOUNTING PRONOUNCEMENTS	NOTE 2 – ACCOUNTING PRONOUNCEMENTS Revenue from Contracts with Customers In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018.

LICENSE, DEVELOPMENT, AND COMME

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS	9 Months Ended
	Sep. 30, 2015
Research and Development Disclosure [Abstract]
LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT	NOTE 3 - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS Egalet Agreement On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone under the tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion. Egalet paid us an upfront payment of $ 5 2.5 one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period. Paragraph IV ANDA Litigation and License Grants On or about September 17, 2012, the FDA began accepting Abbreviated New Drug Applications, or ANDAs, referencing Oxaydo. To date, we have received Paragraph IV Certification Notices under 21 U.S.C. 355(j) (a Paragraph IV Notice) from five separate generic sponsors of an ANDA for a generic drug listing Oxaydo as the reference listed drug. The Paragraph IV Notices state that each generic sponsor believes that our Aversion Technology patents listed in FDA’s Orange Book are invalid, unenforceable or not infringed. We initiated suit against each of Watson Laboratories, Inc. – Florida (Watson), Par Pharmaceutical, Inc., Impax Laboratories, Inc., Sandoz Inc., and Ranbaxy, Inc., each in the United States District Court for the District of Delaware alleging infringement of our U.S. Patent No. 7,510,726 listed in the FDA’s Orange Book. We dismissed our suit against Watson on the grounds that Watson had amended its ANDA from a Paragraph IV Certification to a Paragraph Certification III, which indicated its intent not to market its generic Oxaydo product in advance of our patent expiry. We have entered into distinct Settlement Agreements with each of Par, Impax, Ranbaxy and Sandoz to settle our patent infringement actions. Par is the first filer of an ANDA for a generic Oxaydo product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations. Par is entitled to launch its generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-bearing license from us that would trigger on January 1, 2022. We currently have Orange Book patents that are due to expire between November 2023 and March 2025 10 15 Impax and Sandoz are entitled to launch their generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-free license from us that would trigger 180 days following the first sale of a generic Oxaydo® product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic Oxaydo® product is first sold in the U.S. or November 27, 2021, whichever date occurs first). In certain circumstances, our license to Impax and Sandoz would become effective prior to such time. In certain circumstances, Sandoz may be required to pay us a royalty on net profits of their generic Oxaydo product. Our Settlement Agreement with Ranbaxy provides that Ranbaxy’s current generic of our Oxaydo product that is the subject of its ANDA filing does not infringe our Orange Book listed patents with the FDA. We have not provided Ranbaxy a license to our patents and we may re-commence patent infringement litigation against Ranbaxy if Ranbaxy changes the formulation of its current generic Oxaydo product. Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition. Bayer Agreement On June 15, 2015, we and Bayer entered into a License and Development Agreement ( the “Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine –containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Agreement also grants Bayer first right to negotiate a license to the Impede technology for certain other products. We and Bayer have formed a joint development committee to coordinate development of the Bayer Licensed Product. We will be eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed product in countries with patent coverage and a reduced royalty elsewhere. The term of the Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Agreement in its entirety if the other party materially breaches the Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time. Terminated Pfizer Agreement We had previously entered into a 2007 License, Development and Commercialization Agreement for Oxaydo (named Oxecta™ under a Pfizer trademark) and other Aversion opioid development products with King Pharmaceuticals Research and Development, Inc., which became a subsidiary of Pfizer in 2011 (the “Pfizer Agreement”). By April 2014, we entered into two letter agreements with Pfizer providing for the termination of the Pfizer Agreement and the return of all Aversion product rights to us in exchange for a one-time termination payment of $ 2.0 100 Purdue Pharma The Company received a $ 250

REVENUE RECOGNITION

REVENUE RECOGNITION	9 Months Ended
	Sep. 30, 2015
Revenue Recognition [Abstract]
REVENUE RECOGNITION	NOTE 4 - REVENUE RECOGNITION Revenue is generally realized or realizable and earned when there is persuasive evidence an arrangement exists, delivery has occurred or services rendered, the price is fixed and determinable, and collection is reasonably assured. In connection with our license, development and commercialization agreements, we can recognize milestone revenue, collaboration revenue and royalty revenue. Milestone Revenue Milestone revenue is contingent upon the achievement of certain pre-defined events in the development agreements. Milestone payments are recognized as revenue upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to that milestone. Milestone payments are triggered either by the results of our research and development efforts or by events external to us, such as regulatory approval to market a product. As such, the milestones are substantially at risk at the inception of an agreement, and the amounts of the payments assigned thereto are commensurate with the milestone achieved. In addition, upon the achievement of a milestone event, we have no future performance obligations related to that milestone payment. Each milestone payment is non-refundable and non-creditable when made. In October 2015, Egalet paid us a $ 2.5 Collaboration Revenue Collaboration revenue is derived from reimbursement of development expenses and are recognized when costs are incurred pursuant to the agreement. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreement. We recognized $ 95 Royalties from Pfizer Commencing in February 2013, we began earning royalties based on net sales of Aversion Oxycodone by Pfizer. We earned royalties of approximately $ 4 Product Sales We record revenue from our Nexafed product sales when the price is fixed and determinable at the date of sale, title and risk of ownership have been transferred to the customer, and returns can be reasonably estimated. Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return usually for a period of up to twelve months after the product expiration. The Nexafed products currently have a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers and accordingly we had deferred revenue. During the first quarter of 2015 we determined we had obtained sufficient sales returns history to reasonably estimate future returns from those customers. As a result of this change, we recorded a one-time adjustment in the first quarter of 2015 to recognize revenue that had previously been deferred, resulting in additional net revenues of $ 314 120 255 173 Shipping and Handling Costs We record our shipping and handling costs in selling expenses. The amounts recorded to selling expenses from the shipments of Nexafed products during each of the nine month periods ended September 30, 2015 and 2014 were not material.

RESEARCH AND DEVELOPMENT ACTIVI

RESEARCH AND DEVELOPMENT ACTIVITIES	9 Months Ended
	Sep. 30, 2015
Research and Development [Abstract]
RESEARCH AND DEVELOPMENT ACTIVITIES	NOTE 5 - RESEARCH AND DEVELOPMENT ACTIVITIES Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. We did not have any accrued CRO costs and clinical trial study expenses at either September 30, 2015 or December 31, 2014. We did not have any prepaid CRO costs and clinical trial study expenses at either September 30, 2015 or December 31, 2014.

INVESTMENTS IN MARKETABLE SECUR

INVESTMENTS IN MARKETABLE SECURITIES	9 Months Ended
	Sep. 30, 2015
Investments, Debt and Equity Securities [Abstract]
INVESTMENTS IN MARKETABLE SECURITIES	NOTE 6 - INVESTMENTS IN MARKETABLE SECURITIES September 30, December 31, 2015 2014 Marketable securities: Corporate bonds - maturing within 1 year $ 3.6 $ 3.5 Corporate bonds - maturing after 1 year and through March 2017 1.0 2.8 Exchange-traded funds 7.3 5.0 Total marketable securities $ 11.9 $ 11.3 The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our investments are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs. September 30, 2015 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value Available-for-sale: Corporate bonds $ 4.6 $ - $ - $ 4.6 Exchange-traded funds 7.3 - - 7.3 Total – Current $ 11.9 $ - $ - $ 11.9 December 31, 2014 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value Available-for-sale: Corporate bonds $ 6.3 $ - $ - $ 6.3 Exchange-traded funds 5.0 - - 5.0 Total - Current $ 11.3 $ - $ - $ 11.3 Fair Value Measurement Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement. September 30, 2015 Total Level 1 Level 2 Level 3 Assets: Corporate bonds $ 4.6 $ - $ 4.6 $ - Exchange-traded funds 7.3 7.3 - - Total $ 11.9 $ 7.3 $ 4.6 $ - December 31, 2014 Total Level 1 Level 2 Level 3 Assets: Corporate bonds $ 6.3 $ - $ 6.3 $ - Exchange-traded funds 5.0 5.0 - - Total $ 11.3 $ 5.0 $ 6.3 $ - Accumulated Other Comprehensive Income (Loss) Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). Accumulated other comprehensive income (loss) at September 30, 2015 and December 31, 2014 consisted of unrealized losses on securities of $ 11 13

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 7 – INVENTORIES Inventories may consist of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed products. During 2014, we purchased raw and packaging material inventories for $ 260 260 126 260 27 74 0 201 We had recorded Nexafed deferred revenue of $ 0.35 0.22 Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred. September 30, December 31, 2015 2014 Raw and packaging materials $ - $ 260 Finished goods 148 44 Total 148 304 Less: reserve for finished goods (74) (-) Net $ 74 $ 304

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 8 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment are stated at cost, less accumulated depreciation of $ 1.84 1.79 Our depreciation expense was $ 92 90 Building and improvements 10 - 40 years Land and improvements 20 - 40 years Machinery and equipment 7 - 10 years Scientific equipment 5 - 10 years Computer hardware and software 3 - 10 years

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 9 - ACCRUED EXPENSES September 30, December 31, 2015 2014 Payroll, payroll taxes, and benefits $ 260 $ 94 Professional services 269 253 Franchise taxes 10 13 Property taxes 13 15 Marketing and promotion 120 61 Non-clinical and regulatory services 57 83 Other fees and services 96 49 Total $ 825 $ 568

DEBT

DEBT	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
DEBT	NOTE 10 – DEBT On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $ 10.0 8.35 13.35 260 December 1, 2018 8.00 400 On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the Warrants was lowered from $ 8.00 2.52 33 2.5 5.0 The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 2 1 795 The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $ 50 100 231 10.16 The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non-payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults. Debt Current Long-term Total Balance at Dec 31, 2014 $ 1,758 $ 8,242 $ 10,000 Principal payments (1,160) - (1,160) Classification 1,872 (1,872) - Balance at Sept 30, 2015 $ 2,470 $ 6,370 $ 8,840 Debt Discount Current Long-term Total Balance at Dec 31, 2014 $ - $ (281) $ (281) Modification of warrants - (33) (33) Amortization expense - 94 94 Balance at Sept 30, 2015 $ - $ (220) $ (220) Debt Issuance Costs Current Long-term Total Balance at Dec 31, 2014 $ - $ (162) $ (162) Additions - - - Amortization expense - 50 50 Balance at Sept 30, 2015 $ - $ (112) $ (112) Net Debt at Sept 30, 2015 $ 2,470 $ 6,038 $ 8,508 Three months Ended Nine months Ended September 30, September 30, 2015 2014 2015 2014 Interest expense: Term loan $ 236 $ 257 $ 748 $ 767 Debt discount 31 30 94 89 Debt issue costs 16 17 50 51 Total interest expense $ 283 $ 304 $ 892 $ 907 Calendar Principal Year Payment 2015 $ 598 2016 2,522 2017 2,741 2018 2,979 Total $ 8,840

EQUITY FINANCING

EQUITY FINANCING	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
EQUITY FINANCING	NOTE 11 – EQUITY FINANCING Our universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (“SEC”) on March 15, 2013. On April 18, 2013, we filed a prospectus supplement with the SEC pursuant to which we may sell shares of our common stock from time to time in “at the market” offerings and certain other transactions, having sales proceeds of up to $ 13 54 8 On June 30, 2015, we entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (“Roth”), pursuant to which we engaged Roth to act as sole placement agent in a registered direct offering (the “Offering”) of 1.958 1.958 3.90 Pursuant to the terms of the Placement Agency Agreement, we paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering 35 7.0

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	9 Months Ended
	Sep. 30, 2015
Stockholders Equity Note [Abstract]
COMMON STOCK WARRANTS	NOTE 12 - COMMON STOCK WARRANTS We have outstanding common stock purchase warrants (“warrants”) exercisable for 60 2.52 2.52 Nine months Ended September 30, 2015 2014 Weighted Weighted Average Average Number Exercise Number Exercise (000’s) Price (000’s) Price Outstanding, beginning 60 $ 8.00 431 $ 15.75 Issued - - - - Exercised - - - - Expired - - (371) 17.00 Outstanding, ending 60 $ 2.52 60 $ 8.00

SHARE-BASED COMPENSATION

SHARE-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
SHARE-BASED COMPENSATION	NOTE 13 - SHARE-BASED COMPENSATION Share-based Compensation We have three share-based compensation plans covering stock options and RSUs for our employees and directors. We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the fair-value method. The fair value of the RSUs is the market price of our common stock on the date of grant, less its exercise cost. Three months Ended Nine months Ended September 30, September 30, 2015 2014 2015 2014 Research and development expense: Stock options $ 39 $ 57 $ 117 $ 170 General and administrative expense: Stock options $ 107 $ 141 $ 293 $ 423 Restricted stock units 4 31 51 123 Subtotal $ 111 $ 172 $ 344 $ 546 Total $ 150 $ 229 $ 461 $ 716 Stock Option Award Plans We have one stock option plan in effect, and one stock option plan has expired by its terms, but pursuant to which stock options have been granted and remain outstanding. Nine months Ended September 30, 2015 2014 Number Weighted Weighted of Average Number of Average Options Exercise Options Exercise (000’s) Price (000’s) Price Outstanding, beginning 911 $ 20.7 747 $ 24.95 Granted - - - - Exercised - - (6) 6.50 Forfeited or expired (16) 24.50 (6) 18.00 Outstanding, ending 895 $ 20.66 735 $ 25.15 Options exercisable 779 $ 23.21 674 $ 26.65 No stock options were exercised during the nine months ended September 30, 2015. During the nine months ended September 30, 2014, a total of 6 5 4 36 3 Restricted Stock Unit Award Plans We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award. Nine months Ended September 30, 2015 2014 Number of Number of Number Vested Number Vested of RSUs RSUs of RSUs RSUs Outstanding, beginning 29 29 166 166 Granted 42 - 29 - Distributed (26) (26) (166) (166) Vested - 32 - 22 Forfeited or expired - - - - Outstanding, ending 45 35 29 22 2005 Restricted Stock Unit Award Plan Under our 2005 RSU Plan, 100 66 All RSUs granted under the 2005 RSU Plan had been distributed effective January 1, 2014. 2014 Restricted Stock Unit Award Plan Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 400 330 Information about the awards under the 2014 RSU Plan is as follows: ⋅ On May 1, 2014, we awarded approximately 7 50 25 stock, for up to 40% 26 ⋅ On January 2, 2015, we awarded approximately 10 stock, for up to 40% 33 Information about the distribution of shares under the 2014 RSU Plan is as follows: ⋅ On January 2, 2015, 26 4 26 20 6

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 14 – INCOME TAXES We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both September 30, 2015 and December 31, 2014, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss (“NOL”) carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. We have approximately $ 51.5 151.4 34 2.9 2016 2034 1.1 which expire for the tax years 2024 through 2034 0.3 which expire for the tax years 2015 through 2017

EARNINGS PER SHARE ("EPS")

EARNINGS PER SHARE ("EPS")	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
EARNINGS PER SHARE ("EPS")	NOTE 15 – EARNINGS PER SHARE (“EPS”) Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 13). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2015 and 2014 as the Company reported a net loss for the three and nine month periods, and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive. Three months Ended Nine months Ended September 30, September 30, 2015 2014 2015 2014 EPS – basic and diluted Numerator: net loss $ (2,649) $ (2,904) $ (4,073) $ (10,513) Denominator: Common shares 11,653 9,770 10,432 9,769 Vested RSUs 24 14 14 5 Basic and diluted weighted average shares outstanding 11,677 9,784 10,446 9,774 EPS – basic and diluted $ (0.23) $ (0.30) $ (0.39) $ (1.08) Excluded securities: Common shares issuable: Stock options 895 735 895 735 Nonvested RSUs 10 7 10 7 Common stock warrants 60 60 60 60 Total excluded common shares 965 802 965 802

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 16 – COMMITMENTS AND CONTINGENCIES Purdue Pharma Complaint In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo™ product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “’007 patent”). The complaint seeks injunctive relief as well as awards of damages and attorneys’ fees. We deny the allegations in the complaint, believe they are without merit and are defending the action vigorously. As is the case with patent litigation, there is a risk that the Court may enjoin the making, using, selling and offering for sale Oxaydo and/or may find that Oxaydo infringes the ‘007 patent. As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of September 30, 2015. Reglan ® /Metoclopramide Litigation Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, Acura was served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide. In the Pennsylvania action, over 200 150 50 445 In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by Acura. We discontinued manufacture and distribution of generic metoclopramide more than 18 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing all In Pennsylvania, and California, Generic Defendants, including Acura, also filed dispositive motions based on the Mensing In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions, without prejudice. In July 2013, the Pennsylvania Superior Court issued an adverse decision, and a subsequent appeal to the Pennsylvania Supreme Court was denied. On December 16, 2014, the Generic Defendants filed a Joint Petition for Certiorari with the United States Supreme Court captioned Teva Pharmaceuticals USA, Inc. et al. v. Dorothy Bentley, et al. In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generic Defendants’ appeals from this order were denied by the California appellate courts. In May 2014, the California Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett Mensing As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of September 30, 2015 and we are presently unable to determine if any potential loss would be covered by our insurance carrier. Facility Lease The Company leases administrative office space in Palatine, Illinois under a lease expiring March 31, 2016 25

INVESTMENTS IN MARKETABLE SEC25

INVESTMENTS IN MARKETABLE SECURITIES (Tables)	9 Months Ended
	Sep. 30, 2015
Investments, Debt and Equity Securities [Abstract]
Marketable securities	Investments in marketable securities consisted of the following (in millions): September 30, December 31, 2015 2014 Marketable securities: Corporate bonds - maturing within 1 year $ 3.6 $ 3.5 Corporate bonds - maturing after 1 year and through March 2017 1.0 2.8 Exchange-traded funds 7.3 5.0 Total marketable securities $ 11.9 $ 11.3
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions): September 30, 2015 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value Available-for-sale: Corporate bonds $ 4.6 $ - $ - $ 4.6 Exchange-traded funds 7.3 - - 7.3 Total – Current $ 11.9 $ - $ - $ 11.9 December 31, 2014 Gross Gross Unrealized Unrealized Fair Cost Gains Losses Value Available-for-sale: Corporate bonds $ 6.3 $ - $ - $ 6.3 Exchange-traded funds 5.0 - - 5.0 Total - Current $ 11.3 $ - $ - $ 11.3
Fair Value, Assets Measured on Recurring Basis	Our assets measured at fair value or disclosed at fair value on a recurring basis as at September 30, 2015 and December 31, 2014 consisted of the following (in millions): September 30, 2015 Total Level 1 Level 2 Level 3 Assets: Corporate bonds $ 4.6 $ - $ 4.6 $ - Exchange-traded funds 7.3 7.3 - - Total $ 11.9 $ 7.3 $ 4.6 $ - December 31, 2014 Total Level 1 Level 2 Level 3 Assets: Corporate bonds $ 6.3 $ - $ 6.3 $ - Exchange-traded funds 5.0 5.0 - - Total $ 11.3 $ 5.0 $ 6.3 $ -

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
INVENTORIES	Inventories are summarized as follows (in thousands): September 30, December 31, 2015 2014 Raw and packaging materials $ - $ 260 Finished goods 148 44 Total 148 304 Less: reserve for finished goods (74) (-) Net $ 74 $ 304

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property Plant and Equipment	Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are: Building and improvements 10 - 40 years Land and improvements 20 - 40 years Machinery and equipment 7 - 10 years Scientific equipment 5 - 10 years Computer hardware and software 3 - 10 years

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
ACCRUED EXPENSES	Accrued expenses are summarized as follows (in thousands): September 30, December 31, 2015 2014 Payroll, payroll taxes, and benefits $ 260 $ 94 Professional services 269 253 Franchise taxes 10 13 Property taxes 13 15 Marketing and promotion 120 61 Non-clinical and regulatory services 57 83 Other fees and services 96 49 Total $ 825 $ 568

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Debt	Our debt at September 30, 2015 is summarized below (in thousands): Debt Current Long-term Total Balance at Dec 31, 2014 $ 1,758 $ 8,242 $ 10,000 Principal payments (1,160) - (1,160) Classification 1,872 (1,872) - Balance at Sept 30, 2015 $ 2,470 $ 6,370 $ 8,840 Debt Discount Current Long-term Total Balance at Dec 31, 2014 $ - $ (281) $ (281) Modification of warrants - (33) (33) Amortization expense - 94 94 Balance at Sept 30, 2015 $ - $ (220) $ (220) Debt Issuance Costs Current Long-term Total Balance at Dec 31, 2014 $ - $ (162) $ (162) Additions - - - Amortization expense - 50 50 Balance at Sept 30, 2015 $ - $ (112) $ (112) Net Debt at Sept 30, 2015 $ 2,470 $ 6,038 $ 8,508
Schedule of Interest Expense	Our interest expense during each of the three and nine months ended September 30, 2015 and 2014 consisted of the following (in thousands): Three months Ended Nine months Ended September 30, September 30, 2015 2014 2015 2014 Interest expense: Term loan $ 236 $ 257 $ 748 $ 767 Debt discount 31 30 94 89 Debt issue costs 16 17 50 51 Total interest expense $ 283 $ 304 $ 892 $ 907
Schedule Of Long Term Debt Future Principal Payments Year	Our remaining principal payments on the debt as of September 30, 2015 is as follows (in thousands): Calendar Principal Year Payment 2015 $ 598 2016 2,522 2017 2,741 2018 2,979 Total $ 8,840

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2015
Stockholders Equity Note [Abstract]
Schedule Of Common Stock Warrant Activity	Our common stock warrant activity during the nine months ended September 30, 2015 and 2014 is shown below: Nine months Ended September 30, 2015 2014 Weighted Weighted Average Average Number Exercise Number Exercise (000’s) Price (000’s) Price Outstanding, beginning 60 $ 8.00 431 $ 15.75 Issued - - - - Exercised - - - - Expired - - (371) 17.00 Outstanding, ending 60 $ 2.52 60 $ 8.00

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2015
Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Our share-based compensation expense recognized in the Company’s results of operations comprised the following (in thousands): Three months Ended Nine months Ended September 30, September 30, 2015 2014 2015 2014 Research and development expense: Stock options $ 39 $ 57 $ 117 $ 170 General and administrative expense: Stock options $ 107 $ 141 $ 293 $ 423 Restricted stock units 4 31 51 123 Subtotal $ 111 $ 172 $ 344 $ 546 Total $ 150 $ 229 $ 461 $ 716
Schedule of Share-based Compensation, Stock Options, Activity	Our stock option award activity during the nine months ended September 30, 2015 and 2014 is shown below: Nine months Ended September 30, 2015 2014 Number Weighted Weighted of Average Number of Average Options Exercise Options Exercise (000’s) Price (000’s) Price Outstanding, beginning 911 $ 20.7 747 $ 24.95 Granted - - - - Exercised - - (6) 6.50 Forfeited or expired (16) 24.50 (6) 18.00 Outstanding, ending 895 $ 20.66 735 $ 25.15 Options exercisable 779 $ 23.21 674 $ 26.65
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	A summary of the grants under the RSU Plans consisted of the following (in thousands): Nine months Ended September 30, 2015 2014 Number of Number of Number Vested Number Vested of RSUs RSUs of RSUs RSUs Outstanding, beginning 29 29 166 166 Granted 42 - 29 - Distributed (26) (26) (166) (166) Vested - 32 - 22 Forfeited or expired - - - - Outstanding, ending 45 35 29 22

EARNINGS PER SHARE ("EPS") (Tab

EARNINGS PER SHARE ("EPS") (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share amounts): Three months Ended Nine months Ended September 30, September 30, 2015 2014 2015 2014 EPS – basic and diluted Numerator: net loss $ (2,649) $ (2,904) $ (4,073) $ (10,513) Denominator: Common shares 11,653 9,770 10,432 9,769 Vested RSUs 24 14 14 5 Basic and diluted weighted average shares outstanding 11,677 9,784 10,446 9,774 EPS – basic and diluted $ (0.23) $ (0.30) $ (0.39) $ (1.08) Excluded securities: Common shares issuable: Stock options 895 735 895 735 Nonvested RSUs 10 7 10 7 Common stock warrants 60 60 60 60 Total excluded common shares 965 802 965 802

DESCRIPTION OF BUSINESS -Additi

DESCRIPTION OF BUSINESS -Additional Information (Detail) - Limitx technology [Member] - USD ($) $ in Thousands	14 Months Ended
	Sep. 30, 2015	Aug. 31, 2014
Description of Business [Line Items]
Amount Granted for technology development		$ 300
Amount Received from Grant for technology development	$ 237

LICENSE, DEVELOPMENT, AND COM34

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) - USD ($) $ in Thousands	Oct. 09, 2015	Jan. 07, 2015	Oct. 31, 2015	Mar. 31, 2015	Sep. 30, 2015
License Development and Commercialization Agreement [Line Items]
Percentage Of Inventory Allowance Reserve				100.00%
Licenses Revenue					$ 250
Retail Related Inventory, Total					$ 260
Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Patents expiration year					expire between November 2023 and March 2025
Pfizer Agreement
License Development and Commercialization Agreement [Line Items]
Payment for Termination					$ 2,000
Egalet Agreement
License Development and Commercialization Agreement [Line Items]
Minimum Net Sales Reaching Description					one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Agreement Termination Notice Description					Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
Licenses Revenue		$ 5,000
Proceeds from Milestone Payment On Agreement			$ 2,500
Egalet Agreement | Subsequent Event [Member]
License Development and Commercialization Agreement [Line Items]
Proceeds from Milestone Payment On Agreement	$ 2,500
Minimum | Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty					10.00%
Maximum | Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty					15.00%

REVENUE RECOGNITION - Additiona

REVENUE RECOGNITION - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended			9 Months Ended
	Oct. 31, 2015	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Revenue, Revenue Recognized		$ 95
Sales Returns Liability		173			$ 173
Other Revenue, Net		95	$ 314	$ 0	95	$ 0
Royalty Revenue, Total		$ 0		$ 0	0	$ 4
Cost of Revenue, Total			$ 255
Egalet Agreement [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Proceeds from Milestone Payment On Agreement	$ 2,500
Allowance for Sales Returns [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Sales Returns and Allowances, Goods					$ 120

INVESTMENTS IN MARKETABLE SEC36

INVESTMENTS IN MARKETABLE SECURITIES - Summary of Investments in Marketable Securities (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Marketable securities:
Corporate bonds - maturing within 1 year	$ 3.6	$ 3.5
Corporate bonds - maturing after 1 year and through March 2017	1	2.8
Total marketable securities	11.9	11.3
Exchange-traded funds
Marketable securities:
Total marketable securities	$ 7.3	$ 5

INVESTMENTS IN MARKETABLE SEC37

INVESTMENTS IN MARKETABLE SECURITIES - Fair Value and Unrealized Gains (Losses) related to the Company’s Available-For-Sale Securities (Detail) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Available-for-sale:
Cost	$ 11.9	$ 11.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	11.9	11.3
Corporate Bonds
Available-for-sale:
Cost	4.6	6.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	4.6	6.3
Exchange-traded funds
Available-for-sale:
Cost	7.3	5
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 7.3	$ 5

INVESTMENTS IN MARKETABLE SEC38

INVESTMENTS IN MARKETABLE SECURITIES - Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Assets:
Total marketable securities	$ 11.9	$ 11.3
Corporate bonds
Assets:
Total marketable securities	4.6	6.3
Exchange-traded funds
Assets:
Total marketable securities	7.3	5
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	7.3	5
Fair Value, Inputs, Level 1 | Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 1 | Exchange-traded funds
Assets:
Total marketable securities	7.3	5
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	4.6	6.3
Fair Value, Inputs, Level 2 | Corporate bonds
Assets:
Total marketable securities	4.6	6.3
Fair Value, Inputs, Level 2 | Exchange-traded funds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 | Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 | Exchange-traded funds
Assets:
Total marketable securities	$ 0	$ 0

INVESTMENTS IN MARKETABLE SEC39

INVESTMENTS IN MARKETABLE SECURITIES - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Investment In Marketable Securities [Line Items]
Unrealized losses on securities	$ 2	$ (44)	$ 2	$ 6	$ 13

INVENTORIES (Detail)

INVENTORIES (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw and packaging materials	$ 0	$ 260
Finished goods	148	44
Total	148	304
Less: reserve for finished goods	(74)	0
Net	$ 74	$ 304

INVENTORIES - Additional Inform

INVENTORIES - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross	$ 0			$ 0		$ 260
Inventory Reserve For Raw Materials		$ 260
Deferred Revenue, Current	0			0		353
Oxaydo product [Member]
Inventory [Line Items]
Inventory Reserve For Raw Materials	126			260
Nexafed products [Member]
Inventory [Line Items]
Cost of Goods Sold						220
Deferred Revenue, Current						$ 350
Inventory Reserve For Finished Goods	$ 27		$ 0	$ 74	$ 201

Property, Plant and Equipment42

Property, Plant and Equipment (Detail)	9 Months Ended
	Sep. 30, 2015
Building and improvements | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Building and improvements | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Scientific equipment | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Scientific equipment | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer hardware and software | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer hardware and software | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and equipment | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Machinery and equipment | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Land and improvements | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Land and improvements | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years

Property, Plant and Equipment -

Property, Plant and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Utilities Operating Expense, Depreciation and Amortization	$ 1,840		$ 1,790
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 92	$ 90

ACCRUED EXPENSES (Detail)

ACCRUED EXPENSES (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Line Items]
Payroll, payroll taxes, and benefits	$ 260	$ 94
Professional services	269	253
Franchise taxes	10	13
Property taxes	13	15
Marketing and promotion	120	61
Non-clinical and regulatory services	57	83
Other fees and services	96	49
Total	$ 825	$ 568

DEBT - Additional Information (

DEBT - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Jan. 07, 2015	Oct. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount						$ 10,000
Debt instrument, interest rate, stated percentage						8.35%
Debt default long term debt percentage						13.35%
Debt Instrument, Maturity Date			Dec. 1, 2018
Debt instrument, fee amount			$ 50
Debt consulting placement fee			100
Debt related commitment fees and debt issuance costs			231
Debt instrument unamortized discount			$ 220		$ 281
Warrants to purchase common stock			60
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.52
Debt instrument Cash Maintenance	$ 2,500
Repayments of Debt	$ 5,000		$ 1,160	$ 0
Additions To Debt Instrument Unamortized Discount			33
Debt Instrument, Periodic Payment			260
Debt instrument, periodic payment, principal		$ 1,360	$ 1,160
Debt Instrument, Interest Rate, Effective Percentage			10.16%
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8		$ 8
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52		$ 2.52
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount			$ 400
Warrants to purchase common stock			60
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8
After December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage			1.00%
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid			$ 795
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage			2.00%

DEBT - Summary of Debt (Detail)

DEBT - Summary of Debt (Detail) - USD ($) $ in Thousands	1 Months Ended	9 Months Ended
	Oct. 30, 2015	Sep. 30, 2015
Debt
Balance at Dec 31, 2014	$ 8,840	$ 10,000
Principal payments	(1,360)	(1,160)
Classification		0
Balance at Sept 30, 2015		8,840
Debt Discount
Balance at Dec 31, 2014	(220)	(281)
Modification of warrants		33
Amortization expense		94
Balance at Sept 30, 2015		(220)
Debt Issuance Costs
Balance at Dec 31, 2014	(112)	(162)
Additions		0
Amortization expense		50
Balance at Sept 30, 2015		(112)
Net Debt		8,508
Long-term [Member]
Debt
Balance at Dec 31, 2014	6,370	8,242
Principal payments		0
Classification		(1,872)
Balance at Sept 30, 2015		6,370
Debt Discount
Balance at Dec 31, 2014	(220)	(281)
Modification of warrants		(33)
Amortization expense		94
Balance at Sept 30, 2015		(220)
Debt Issuance Costs
Balance at Dec 31, 2014	(112)	(162)
Additions		0
Amortization expense		50
Balance at Sept 30, 2015		(112)
Net Debt		6,038
Current [Member]
Debt
Balance at Dec 31, 2014	2,470	1,758
Principal payments		(1,160)
Classification		1,872
Balance at Sept 30, 2015		2,470
Debt Discount
Balance at Dec 31, 2014	0	0
Modification of warrants		0
Amortization expense		0
Balance at Sept 30, 2015		0
Debt Issuance Costs
Balance at Dec 31, 2014	$ 0	0
Additions		0
Amortization expense		0
Balance at Sept 30, 2015		0
Net Debt		$ 2,470

DEBT - Interest Expense (Detail

DEBT - Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Interest expense:
Term loan	$ 236	$ 257	$ 748	$ 767
Debt discount	31	30	94	89
Debt issue costs	16	17	50	51
Total interest expense	$ 283	$ 304	$ 892	$ 907

DEBT - Long-Term Debt (Detail)

DEBT - Long-Term Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
2,015	$ 598
2,016	2,522
2,017	2,741
2,018	2,979
Total	$ 8,840	$ 10,000

EQUITY FINANCING - Additional I

EQUITY FINANCING - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	1 Months Ended	6 Months Ended	9 Months Ended
	Apr. 18, 2013	Jun. 30, 2015	Sep. 30, 2015
Equity Financing [Line Items]
Proceeds from sale of common stock	$ 13,000
Sale leaseback transaction, transaction costs, financing activities			$ 8
Sale leaseback transaction, net proceeds, financing activities			217
Common Stock [Member]
Equity Financing [Line Items]
Proceeds from sale of common stock			$ 225
Stock issued during period, shares, new issues			54
Placement Agency Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues		1,958
Share price		$ 0.01
Proceeds from issuance of private placement		$ 7,000
Description for repayment of placement agent		paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering
Placement agency reimbursed for expenses		$ 35
Securities Purchase Agreement [Member]
Equity Financing [Line Items]
Stock issued during period, shares, new issues		1,958
Share price		$ 3.90
Proceeds from issuance of private placement		$ 7,630

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule Of Common Stock Warrant Activity (Detail) - Warrant [Member] - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Number of Options
Number of Options Outstanding, beginning	60	431
Number of Options, Issued	0	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	(371)
Number of Options Outstanding, ending	60	60
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 8	$ 15.75
Issued	0	0
Exercised	0	0
Expired	0	17
Weighted Average Exercise Price, ending	$ 2.52	$ 8

COMMON STOCK WARRANTS - Additio

COMMON STOCK WARRANTS - Additional Information (Detail) shares in Thousands	9 Months Ended
	Sep. 30, 2015$ / sharesshares
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 2.52
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Common stock Warrant expiration date	December 27, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 8

SHARE-BASED COMPENSATION - Reco

SHARE-BASED COMPENSATION - Recognition of Share-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	$ 432	$ 955	$ 1,907	$ 3,674
General and administrative expense	111	172	344	546
Share Based Compensation Expense Recognized In Operations	150	229	461	716
Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	39	57	117	170
General and administrative expense	107	141	293	423
Restricted Stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	$ 4	$ 31	$ 51	$ 123

SHARE-BASED COMPENSATION - Stoc

SHARE-BASED COMPENSATION - Stock Option Award Activity (Detail) - Stock Option Plan [Member] - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	911	747
Number of Options, Granted	0	0
Number of Options, Exercised	0	(6)
Number of Options, Forfeited or expired	(16)	(6)
Number of Options Outstanding, ending	895	735
Number of Options exercisable	779	674
Weighted Average Exercise Price, beginning	$ 20.7	$ 24.95
Weighted Average Exercise Price, Granted	0	0
Weighted Average Exercise Price, Exercised	0	6.50
Weighted Average Exercise Price, Forfeited or expired	24.50	18
Weighted Average Exercise Price, ending	20.66	25.15
Weighted Average Exercise Price, Options exercisable	$ 23.21	$ 26.65

SHARE-BASED COMPENSATION - Summ

SHARE-BASED COMPENSATION - Summary of RSU Plan (Detail) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	42	29
Distributed	(26)	(166)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	45	29
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	0	0
Distributed	(26)	(166)
Vested	32	22
Forfeited or expired	0	0
Outstanding, ending	35	22

SHARE-BASED COMPENSATION - Addi

SHARE-BASED COMPENSATION - Additional Information (Detail) - USD ($) shares in Thousands, $ in Thousands	Jan. 02, 2015	May. 01, 2014	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Jan. 31, 2014	Jan. 02, 2015	Sep. 30, 2015	Sep. 30, 2014
Stock options [Member]
Employee Benefit Plans Disclosure [Line Items]
Withholding tax obligations									$ 36
Shares withheld upon elections made to exchange RSUs									4
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									6
Option Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period									5
Stock Issued During Period Shares Stock Options Exercised Net Of Shares For Tax Withholdings									3
2005 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Shares withheld upon elections made to exchange RSUs						66
Restricted Stock Units Exchanged In Satisfaction Of Withholding Tax Obligations						$ 500
Number of vested shares distributed to holders						100
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									165
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights								one-fourth of vested shares of common stock underlying RSU awards of 0.66 million shares were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	26						26
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution							4
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award								330
Deferred Compensation Arrangement with Individual, Recorded Liability								$ 33
2014 Restricted Stock Unit Award Plan [Member] | Settled In Cash [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							6
2014 Restricted Stock Unit Award Plan [Member] | Distributed In Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							26
2014 Restricted Stock Unit Award Plan [Member] | Convertible Common Stock [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period							20
2014 Restricted Stock Unit Award Plan [Member] | Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	10	7
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%	25.00%	50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description	stock, for up to 40%	stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value			$ 26

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Income Tax Disclosure [Line Items]
Federal income tax benefits		$ 51.5
Federal NOLs		$ 151.4
U.S. statutory tax rate		34.00%
State income tax benefits		$ 2.9
Federal Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits		1.1
Research and development expiration period	which expire for the tax years 2024 through 2034
Indiana State Research and Development
Income Tax Disclosure [Line Items]
Research and development tax credits		$ 0.3
Research and development expiration period	which expire forthe tax years 2015 through 2017
Maximum
Income Tax Disclosure [Line Items]
NOL expiration year		2,034
Minimum
Income Tax Disclosure [Line Items]
NOL expiration year		2,016

EARNINGS PER SHARE ("EPS") - Re

EARNINGS PER SHARE ("EPS") - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
EPS - basic and diluted
Numerator: net loss	$ (2,649)	$ (2,904)	$ (4,073)	$ (10,513)
Denominator:
Common shares	11,653	9,770	10,432	9,769
Vested RSUs	24	14	14	5
Basic and diluted weighted average shares outstanding	11,677	9,784	10,446	9,774
EPS - basic and diluted	$ (0.23)	$ (0.3)	$ (0.39)	$ (1.08)
Common shares issuable:
Total excluded common shares	965	802	965	802
Stock options
Common shares issuable:
Total excluded common shares	895	735	895	735
Nonvested RSUs member
Common shares issuable:
Total excluded common shares	10	7	10	7
Common stock warrants
Common shares issuable:
Total excluded common shares	60	60	60	60

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	150
Number of lawsuits served	50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint	445
Palatine Lllinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space	$ 25
Lease expiring date	March 31, 2016